| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.25 | 4e-10 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-08 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.3 | 7e-08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-07 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-06 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 6e-06 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.15 | 1e-05 |